Category Archives: biotechnology stocks

Emerchants Ltd – Signing Multi-Year Agreements

Signing multi-year agreements: Emerchants Ltd (ASX: EML)recently announced that it has entered into a multi-year agreement with online corporate bookmakers, Hillside (Sports) GP Limited and Hillside (Gibralter) Limited (bet365), to offer their customers the Emerchants payments card for their customers in the U.K. For the first half financial results, revenue increased 108% to $10.6 million compared to same period prior

Read more

CSL Limited Global Scale And Unique Business Model

Global scale and unique business model: CSL Ltd (ASX: CSL) is up 4.32% in the last five days (as at April 20, 2016) and has grown in scale to become global leader through organic and acquisition route. The Board has implemented numerous on market share buybacks in recent years, boosting EPS (announced $1 billion on October 2015 while finished 53%

Read more

Viralytics Ltd Fund Raising To Advance Clinical Programme

Fund raising to advance clinical programme: Viralytics Limited (ASX: VLA) recently presented positive initial data for its ongoing clinical trials on CAVATAK with checkpoint inhibitor YERVOY® in late stage melanoma patients. CAVATAK has also indicated anti-cancer immune activity increase as per CALM extension study. Accordingly, the stock surged 17.4% on April 19, 2016. VLA had some time back announced for

Read more

Bionomics Ltd Strong Revenues Performance

Strong revenues performance:Bionomics Limited (ASX: BNO) reported revenues of $10.21 million for first half of 2016 as compared with $7.32 million in the prior corresponding period (pcp) but reported a loss $9.69 million against $5.68 million in pcp. Accordingly, the group’s stock fell over 36.54% in the last six months (as of April 19, 2016). On the other hand, the

Read more

Starpharma Holdings Ltd Product Development And Marketing Tie-Ups

Product development and marketing tie-ups: Starpharma Holding Ltd (ASX: SPL) announced results for its most recent DEP™ candidate, DEP™ cabazitaxel used in human breast cancer model. It had also announced the licensing by Adama of Starpharma’s Priostar® dendrimer technology for development and commercialization of an enhanced, proprietary 2, 4-D herbicide for the US market. Under the license, Starpharma would get

Read more

Prana Biotechnology Ltd Clinical Trials Updates

Clinical trials updates: Prana Biotechnology Ltd (ASX: PBT) recently announced for regaining compliance with NASDAQ Listing requirements. On the other hand, PBT’s revenue decreased to $77,328 for the first half of 2016 against $92,581 in H1FY15 due to the decrease in amounts of cash being carried in interest bearing accounts. It has incurred a loss of $2.85 million as compared

Read more
« Older Entries